Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow

Liknande verk

• The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow
  av: Lange, Andrzej, et al.
  Publicerad: (2018)
• Anti-CMV-IgG Positivity of Donors Is Beneficial for alloHSCT Recipients with Respect to the Better Short-Term Immunological Recovery and High Level of CD4+CD25high Lymphocytes
  av: Jaskula, Emilia, et al.
  Publicerad: (2015)
• Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
  av: Lange, Andrzej, et al.
  Publicerad: (2021)
• Intra-bone donor lymphocyte infusion at relapse: clinical outcome is associated with presence of CD8+ cells in the marrow
  av: Lange, Andrzej, et al.
  Publicerad: (2019)
• Fifteen-year follow-up of patients with critical limb ischaemia after local cellular therapy: the long-term positive effect is due to the presence of CD45– CD34– and CD34+ cells in the inoculum
  av: Lange, Andrzej, et al.
  Publicerad: (2019)